Profiel
Paul McInulty is currently the Senior Vice President-Regulatory Affairs at Arvinas, Inc. Prior to this, he worked as the Vice President-Therapeutic Head & Hematology at Bristol Myers Squibb Co. and as the Vice President-Regulatory Affairs at Celgene Corp.
He completed his undergraduate degree at The University of Sheffield.
Actieve functies van Paul McInulty
| Bedrijven | Functie | Begin |
|---|---|---|
| ARVINAS, INC. | General Counsel | 03-10-2022 |
Eerdere bekende functies van Paul McInulty
| Bedrijven | Functie | Einde |
|---|---|---|
| CELGENE | General Counsel | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Opleiding van Paul McInulty
| The University of Sheffield | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARVINAS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
